KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accumulated Expenses: 2011-2025

Historic Accumulated Expenses for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $295.8 million.

  • Sarepta Therapeutics' Accumulated Expenses fell 14.22% to $295.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.8 million, marking a year-over-year decrease of 14.22%. This contributed to the annual value of $373.5 million for FY2024, which is 18.58% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Accumulated Expenses of $295.8 million as of Q3 2025, which was down 21.62% from $377.4 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Accumulated Expenses ranged from a high of $419.0 million in Q4 2022 and a low of $180.6 million during Q1 2021.
  • Over the past 3 years, Sarepta Therapeutics' median Accumulated Expenses value was $344.8 million (recorded in 2024), while the average stood at $338.8 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 66.96% in 2022, then fell by 24.82% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Accumulated Expenses (Quarterly) stood at $271.7 million in 2021, then soared by 54.21% to $419.0 million in 2022, then declined by 24.82% to $315.0 million in 2023, then grew by 18.58% to $373.5 million in 2024, then decreased by 14.22% to $295.8 million in 2025.
  • Its Accumulated Expenses was $295.8 million in Q3 2025, compared to $377.4 million in Q2 2025 and $391.6 million in Q1 2025.